Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M.

J Neurooncol. 2012 Jan;106(1):147-53. doi: 10.1007/s11060-011-0650-1. Epub 2011 Jul 8.

2.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC).; Canadian Brain Tumor Consortium.; CENTRIC study team..

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

PMID:
25163906
3.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium..

Cancer. 2012 Nov 15;118(22):5601-7. doi: 10.1002/cncr.27585. Epub 2012 Apr 19.

4.

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.

Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S.

Neuro Oncol. 2015 Oct;17(10):1386-92. doi: 10.1093/neuonc/nov085. Epub 2015 May 24.

5.

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB.

J Clin Oncol. 2008 Dec 1;26(34):5610-7. doi: 10.1200/JCO.2008.16.7510. Epub 2008 Nov 3.

PMID:
18981465
6.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA.

Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11.

7.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
8.

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Reardon DA, Nabors LB, Stupp R, Mikkelsen T.

Expert Opin Investig Drugs. 2008 Aug;17(8):1225-35. doi: 10.1517/13543784.17.8.1225 . Review.

9.

Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.

MacDonald TJ, Vezina G, Stewart CF, Turner D, Pierson CR, Chen L, Pollack IF, Gajjar A, Kieran MW.

Neuro Oncol. 2013 Oct;15(10):1438-44. doi: 10.1093/neuonc/not058. Epub 2013 Sep 5.

10.

Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.

Scaringi C, Minniti G, Caporello P, Enrici RM.

Anticancer Res. 2012 Oct;32(10):4213-23. Review.

PMID:
23060541
11.

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R.

Future Oncol. 2011 Mar;7(3):339-54. doi: 10.2217/fon.11.8.

PMID:
21417900
12.

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.

Eisele G, Wick A, Eisele AC, Clément PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M.

J Neurooncol. 2014 Mar;117(1):141-5. doi: 10.1007/s11060-014-1365-x. Epub 2014 Jan 19.

PMID:
24442484
13.

Cilengitide treatment for malignant glioma: current status and future direction.

Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I.

Neurol Med Chir (Tokyo). 2012;52(8):539-47. Review.

14.

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE.

J Clin Oncol. 2008 Feb 20;26(6):919-24. doi: 10.1200/JCO.2007.14.1812.

PMID:
18281665
15.

Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery.

Zhao YZ, Lin Q, Wong HL, Shen XT, Yang W, Xu HL, Mao KL, Tian FR, Yang JJ, Xu J, Xiao J, Lu CT.

J Control Release. 2016 Feb 28;224:112-25. doi: 10.1016/j.jconrel.2016.01.015. Epub 2016 Jan 11.

PMID:
26792571
16.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD.

Melanoma Res. 2012 Aug;22(4):294-301. doi: 10.1097/CMR.0b013e32835312e4.

17.

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J; NABTT CNS Consortium..

Clin Cancer Res. 2010 Apr 15;16(8):2443-9. doi: 10.1158/1078-0432.CCR-09-3106. Epub 2010 Apr 6.

18.

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.

Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M.

Neuro Oncol. 2009 Dec;11(6):747-56. doi: 10.1215/15228517-2009-012.

19.

[Cilengitide: a new weapon against glioblastoma?].

[No authors listed]

Tumori. 2008 Sep-Oct;94(5):suppl 1-2. Italian. No abstract available.

PMID:
19112962
20.

Combination therapy of cilengitide with belotecan against experimental glioblastoma.

Kim YH, Lee JK, Kim B, DeWitt JP, Lee JE, Han JH, Kim SK, Oh CW, Kim CY.

Int J Cancer. 2013 Aug 1;133(3):749-56. doi: 10.1002/ijc.28058. Epub 2013 Feb 27.

Supplemental Content

Support Center